<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>BioMed Central</PublisherName>
    <PublisherLocation>London</PublisherLocation>
    <PublisherImprintName>BioMed Central</PublisherImprintName>
  </PublisherInfo>
  <Journal OutputMedium="Online">
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>12943</JournalID>
      <JournalElectronicISSN>1476-4598</JournalElectronicISSN>
      <JournalTitle>Molecular Cancer</JournalTitle>
      <JournalAbbreviatedTitle>Mol Cancer</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="SCB" Type="Primary">Biomedicine</JournalSubject>
        <JournalSubject Code="SCB11001" Priority="1" Type="Secondary">Cancer Research</JournalSubject>
        <JournalSubject Code="SCH33160" Priority="2" Type="Secondary">Oncology</JournalSubject>
        <SubjectCollection Code="Biomedical and Life Sciences">SC3</SubjectCollection>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume OutputMedium="Online">
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>15</VolumeIDStart>
        <VolumeIDEnd>15</VolumeIDEnd>
        <VolumeIssueCount>1</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular" OutputMedium="Online">
        <IssueInfo IssueType="Regular" TocLevels="0">
          <IssueIDStart>1</IssueIDStart>
          <IssueIDEnd>1</IssueIDEnd>
          <IssueArticleCount>0</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2016</Year>
              <Month>12</Month>
            </CoverDate>
            <PricelistYear>2016</PricelistYear>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>The Author(s)</CopyrightHolderName>
            <CopyrightYear>2016</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="s12943-016-0531-5" OutputMedium="Online">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="Yes" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>531</ArticleID>
            <ArticleDOI>10.1186/s12943-016-0531-5</ArticleDOI>
            <ArticleCitationID>46</ArticleCitationID>
            <ArticleSequenceNumber>46</ArticleSequenceNumber>
            <ArticleTitle Language="En" OutputMedium="All">Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model</ArticleTitle>
            <ArticleCategory>Research</ArticleCategory>
            <ArticleFirstPage>1</ArticleFirstPage>
            <ArticleLastPage>12</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2016</Year>
                <Month>5</Month>
                <Day>31</Day>
              </RegistrationDate>
              <Received>
                <Year>2015</Year>
                <Month>8</Month>
                <Day>28</Day>
              </Received>
              <Accepted>
                <Year>2016</Year>
                <Month>5</Month>
                <Day>31</Day>
              </Accepted>
              <OnlineDate>
                <Year>2016</Year>
                <Month>6</Month>
                <Day>10</Day>
              </OnlineDate>
            </ArticleHistory>
            <ArticleFundingInformation>
              <Fund>
                <FunderName FundRefID="http://dx.doi.org/10.13039/501100004663">Ministry of Science and Technology, Taiwan (TW)</FunderName>
                <GrantNumber GrantRecipient="Au7" Type="FundRef">MOST 103-2314-B-006-060-MY2 and NSC 100-2325-B-400-012</GrantNumber>
              </Fund>
              <Fund>
                <FunderName FundRefID="http://dx.doi.org/10.13039/501100004663">Ministry of Science and Technology, Taiwan (TW)</FunderName>
                <GrantNumber GrantRecipient="Au6" Type="FundRef">NSC 101-2325-B-400-010 and NSC 102-2325-B-400 -010</GrantNumber>
              </Fund>
              <Fund>
                <FunderName FundRefID="http://dx.doi.org/10.13039/501100004663">Ministry of Science and Technology, Taiwan</FunderName>
                <GrantNumber GrantRecipient="Au1" Type="FundRef">MOST 104-2320-B-038-065</GrantNumber>
              </Fund>
              <Fund>
                <FunderName>Taipei Medical University, Taipei, Taiwan</FunderName>
                <GrantNumber GrantRecipient="Au1" Type="FundRef">TMU103-AE1-B28</GrantNumber>
              </Fund>
              <Fund>
                <FunderName>Chi Mei Medical Center, Tainan, Taiwan</FunderName>
                <GrantNumber GrantRecipient="Au7" Type="FundRef">CMNCKU10422</GrantNumber>
              </Fund>
            </ArticleFundingInformation>
            <ArticleCopyright>
              <CopyrightHolderName>Chiu et al.</CopyrightHolderName>
              <CopyrightYear>2016</CopyrightYear>
              <License SubType="CC BY + CC0" Type="OpenAccess" Version="4.0">
                <SimplePara>
                           <Emphasis Type="Bold">Open Access</Emphasis>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ExternalRef>
                    <RefSource>http://creativecommons.org/licenses/by/4.0/</RefSource>
                    <RefTarget Address="http://creativecommons.org/licenses/by/4.0/" TargetType="URL"/>
                  </ExternalRef>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ExternalRef>
                    <RefSource>http://creativecommons.org/publicdomain/zero/1.0/</RefSource>
                    <RefTarget Address="http://creativecommons.org/publicdomain/zero/1.0/" TargetType="URL"/>
                  </ExternalRef>) applies to the data made available in this article, unless otherwise stated.</SimplePara>
              </License>
            </ArticleCopyright>
            <ArticleGrants Type="OpenChoice">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="OpenAccess"/>
              <BodyHTMLGrant Grant="OpenAccess"/>
              <BibliographyGrant Grant="OpenAccess"/>
              <ESMGrant Grant="OpenAccess"/>
            </ArticleGrants>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1 Aff2" EqualContribution="Yes" ID="Au1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Hui-Wen</GivenName>
                  <FamilyName>Chiu</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff3" ID="Au2">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Ya-Ling</GivenName>
                  <FamilyName>Yeh</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff4 Aff5" ID="Au3">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Yi-Ching</GivenName>
                  <FamilyName>Wang</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff6" ID="Au4">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Wei-Jan</GivenName>
                  <FamilyName>Huang</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff7 Aff8" EqualContribution="Yes" ID="Au5">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Sheng-Yow</GivenName>
                  <FamilyName>Ho</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff9" CorrespondingAffiliationID="Aff9" ID="Au6">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Pinpin</GivenName>
                  <FamilyName>Lin</FamilyName>
                </AuthorName>
                <Contact>
                  <Phone>886-37-246166</Phone>
                  <Fax>886-37-587406</Fax>
                  <Email>pplin@nhri.org.tw</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff3 Aff10 Aff11" CorrespondingAffiliationID="Aff3" ID="Au7">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Ying-Jan</GivenName>
                  <FamilyName>Wang</FamilyName>
                </AuthorName>
                <Contact>
                  <Phone>886-6-235-3535</Phone>
                  <Fax>886-6-2752484</Fax>
                  <Email>yjwang@mail.ncku.edu.tw</Email>
                </Contact>
              </Author>
              <Affiliation ID="Aff1">
                <OrgDivision>Division of Nephrology, Department of Internal Medicine</OrgDivision>
                <OrgName>Shuang Ho Hospital, Taipei Medical University</OrgName>
                <OrgAddress>
                  <City>Taipei</City>
                  <Country Code="TW">Taiwan</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff2">
                <OrgName>Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University</OrgName>
                <OrgAddress>
                  <City>Taipei</City>
                  <Country Code="TW">Taiwan</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff3">
                <OrgDivision>Department of Environmental and Occupational Health</OrgDivision>
                <OrgName>College of Medicine, National Cheng Kung University</OrgName>
                <OrgAddress>
                  <Street>138 Sheng-Li Road</Street>
                  <City>Tainan</City>
                  <Country Code="TW">Taiwan</Country>
                  <Postcode>704</Postcode>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff4">
                <OrgName>Institute of Basic Medical Sciences, National Cheng Kung University</OrgName>
                <OrgAddress>
                  <City>Tainan</City>
                  <Country Code="TW">Taiwan</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff5">
                <OrgDivision>Department of Pharmacology</OrgDivision>
                <OrgName>National Cheng Kung University</OrgName>
                <OrgAddress>
                  <City>Tainan</City>
                  <Country Code="TW">Taiwan</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff6">
                <OrgName>Graduate Institute of Pharmacognosy, Taipei Medical University</OrgName>
                <OrgAddress>
                  <City>Taipei</City>
                  <Country Code="TW">Taiwan</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff7">
                <OrgDivision>Department of Radiation Oncology, Chi Mei Medical Center</OrgDivision>
                <OrgName>Liouying</OrgName>
                <OrgAddress>
                  <City>Tainan</City>
                  <Country Code="TW">Taiwan</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff8">
                <OrgName>Chang Jung Christian University</OrgName>
                <OrgAddress>
                  <City>Tainan</City>
                  <Country Code="TW">Taiwan</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff9">
                <OrgName>National Institute of Environmental Health Sciences, National Health Research Institutes</OrgName>
                <OrgAddress>
                  <Street>No. 35 Keyan Road</Street>
                  <City>Zhunan Town</City>
                  <State>Miaoli County</State>
                  <Postcode>350</Postcode>
                  <Country Code="TW">Taiwan</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff10">
                <OrgDivision>Department of Biomedical Informatics</OrgDivision>
                <OrgName>Asia University</OrgName>
                <OrgAddress>
                  <City>Taichung</City>
                  <Country Code="TW">Taiwan</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff11">
                <OrgDivision>Department of Medical Research</OrgDivision>
                <OrgName>China Medical University Hospital, China Medical University</OrgName>
                <OrgAddress>
                  <City>Taichung</City>
                  <Country Code="TW">Taiwan</Country>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En" OutputMedium="All">
              <Heading>Abstract</Heading>
              <AbstractSection ID="ASec1">
                <Heading>Background</Heading>
                <Para ID="Par1">Triple-negative breast cancer (TNBC) is the most aggressive and invasive of the breast cancer subtypes. TNBC is a challenging disease that lacks targets for treatment. Histone deacetylase inhibitors (HDACi) are a group of targeted anticancer agents that enhance radiosensitivity. Bcl-2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) is a member of the Bcl-2 subfamily. BNIP3 is not found in normal breast tissue but is up-regulated in breast cancer. In the present study, we investigated the anti-cancer effects of a newly developed HDACi, YCW1, combined with ionizing radiation (IR) in TNBC in vitro and in an orthotopic mouse model. Furthermore, we examined the relationship between autophagy and BNIP3.</Para>
              </AbstractSection>
              <AbstractSection ID="ASec2">
                <Heading>Methods</Heading>
                <Para ID="Par2">Trypan blue exclusion was used to investigate the viability of 4 T1 (a mouse TNBC cell line) and MDA-MB-231 cells (a human TNBC cell line) following combined YCW1 and IR treatment. Flow cytometry was used to determine apoptosis and autophagy. The expression levels of BNIP3, endoplasmic reticulum (ER) stress- and autophagic-related proteins were measured using western blot analysis. An orthotopic mouse model was used to investigate the in vivo effects of YCW1 and IR alone and in combination. Tumor volumes were monitored using a bioluminescence-based IVIS Imaging System 200.</Para>
              </AbstractSection>
              <AbstractSection ID="ASec3">
                <Heading>Results</Heading>
                <Para ID="Par3">We found that YCW1 significantly enhanced toxicity in 4 T1 cells compared with suberoylanilide hydroxamic acid (SAHA), which was the first HDACi approved by the Food and Drug Administration for clinical use in cancer patients. The combined treatment of YCW1 and IR enhanced cytotoxicity by inducing ER stress and increasing autophagy induction. Additionally, the combined treatment caused autophagic flux and autophagic cell death. Furthermore, the expression level of BNIP3 was significantly decreased in cells following combined treatment. The downregulation of BNIP3 led to a significant increase in autophagy and cytotoxicity. The combined anti-tumor effects of YCW1 and IR were also observed in an orthotopic mouse model; combination therapy resulted in a significant increase in autophagy and decreased tumor tissue expression of BNIP3 in the tumor tissue.</Para>
              </AbstractSection>
              <AbstractSection ID="ASec4">
                <Heading>Conclusions</Heading>
                <Para ID="Par4">These data support the possibility of using a combination of HDACi and IR in the treatment of TNBC. Moreover, BNIP3 may be a potential target protein for TNBC treatment.</Para>
              </AbstractSection>
            </Abstract>
            <KeywordGroup Language="En" OutputMedium="All">
              <Heading>Keywords</Heading>
              <Keyword>Histone deacetylase inhibitor</Keyword>
              <Keyword>Radiation</Keyword>
              <Keyword>Triple-negative breast cancer</Keyword>
              <Keyword>Autophagy</Keyword>
            </KeywordGroup>
            <ArticleNote Type="ESMHint">
              <Heading>Electronic supplementary material</Heading>
              <SimplePara>The online version of this article (doi:<ExternalRef>
                  <RefSource>10.1186/s12943-016-0531-5</RefSource>
                  <RefTarget Address="10.1186/s12943-016-0531-5" TargetType="DOI"/>
                </ExternalRef>) contains supplementary material, which is available to authorized users.</SimplePara>
            </ArticleNote>
          </ArticleHeader>
          <Body>
            <Section1 ID="Sec1" Type="Introduction">
              <Heading>Background</Heading>
              <Para ID="Par5">Triple-negative breast cancer (TNBC) characterized by the absence of estrogen receptor alpha (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) expression, is a basal-like subgroup of breast cancers that accounts for 10–20 % of all breast cancers [<CitationRef CitationID="CR1">1</CitationRef>]. Patients with this subtype are more likely to develop recurrence within the first 5 years, and survival following metastatic relapse is shorter for TNBC patients than those with other breast cancer subtypes [<CitationRef CitationID="CR2">2</CitationRef>]. Currently, TNBC is one of the most attractive areas in cancer research. One reason for this scientific interest is the lack of therapeutic targets for TNBC. Therefore, identifying biological markers of TNBC progression could be helpful for the prevention of breast cancer metastasis and could provide novel therapeutic strategies for the disease. TNBC is typically treated with surgery, radiotherapy, and chemotherapy. Overcoming the deleterious consequences of radiotherapy and maximizing its anti-tumor effects to control tumor progression should be the goal of combined radio- and chemotherapy. Combination therapies aim to enhance radiosensitivity and prevent tumor recurrence. Numerous conventional cytotoxic drugs are used in conjunction with different radiation techniques [<CitationRef CitationID="CR3">3</CitationRef>]. Recently, data accumulated by us and others have revealed that some compounds or drugs enhanced radiosensitivity through regulation of the cell cycle, induction of cell death and inhibition of DNA repair [<CitationRef CitationID="CR1">1</CitationRef>, <CitationRef CitationID="CR4">4</CitationRef>–<CitationRef CitationID="CR6">6</CitationRef>].</Para>
              <Para ID="Par6">Ionizing radiation (IR) induces important signal transduction pathways, such as the PI3K pathway, that are linked with radioprotective and growth-promoting events [<CitationRef CitationID="CR7">7</CitationRef>]. The PI3K signaling pathway is associated with major radioresistance mechanisms, such as intrinsic radiosensitivity, tumor cell proliferation and hypoxia [<CitationRef CitationID="CR8">8</CitationRef>]. Downstream molecular targets of PI3K up-regulate hypoxia-related proteins, stimulate mitogenic and pro-survival pathways and have anti-apoptotic effects via the induction of Bcl-XL, which is a member of the Bcl-2 family, and the inactivation of Bad and procaspase-9 [<CitationRef CitationID="CR9">9</CitationRef>]. Positive Bcl-2 expression has been associated with poor survival and reduced sensitivity to chemotherapy in patients with TNBC [<CitationRef CitationID="CR10">10</CitationRef>]. Bcl-2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) is a member of the Bcl-2 subfamily of death-inducing mitochondrial proteins [<CitationRef CitationID="CR11">11</CitationRef>]. Previous studies have demonstrated that BNIP3 provides a survival advantage in cancer cells by promoting autophagy and eliminating damaged mitochondria with low membrane potential that are a source of intracellular ROS [<CitationRef CitationID="CR12">12</CitationRef>, <CitationRef CitationID="CR13">13</CitationRef>]. Additionally, BNIP3 expression is restricted to few normal tissues, including skeletal muscle and brain [<CitationRef CitationID="CR14">14</CitationRef>]. In contrast to normal breast tissue in which BNIP3 was not expressed up-regulation of BNIP3 was observed in breast cancer [<CitationRef CitationID="CR15">15</CitationRef>]. However, whether BNIP3 has an important role in TBNC remains unknown.</Para>
              <Para ID="Par7">Many studies have implicated that HDAC enzymes have a role in the development of cancer and, therefore, are potential therapeutic targets [<CitationRef CitationID="CR16">16</CitationRef>, <CitationRef CitationID="CR17">17</CitationRef>]. HDAC inhibitors (HDACi) block the deacetylation function of HDACs, causing cell cycle arrest, endoplasmic reticulum (ER) stress, differentiation, inhibition of angiogenesis, apoptosis and autophagy in many tumors [<CitationRef CitationID="CR6">6</CitationRef>, <CitationRef CitationID="CR17">17</CitationRef>]. Normal cells are relatively resistant to HDACi-induced cell death [<CitationRef CitationID="CR18">18</CitationRef>]. Moreover, HDACi can affect apoptosis and autophagy through regulation of the Bcl-2 family including inhibition of Bcl-2 and activation of Bax [<CitationRef CitationID="CR19">19</CitationRef>]. However, several serious adverse events were reported in patients treated with suberoylanilide hydroxamic acid (SAHA), which was the first HDACi approved by the US Food and Drug Administration (FDA) for the clinical treatment of cutaneous T-cell lymphoma, and other HDACi [<CitationRef CitationID="CR20">20</CitationRef>]. Therefore, the development of novel HDACi combination therapies or new HDACi with improved efficacies is urgently needed, particularly for solid tumors.</Para>
              <Para ID="Par8">In this study, we used a newly developed HDACi, YCW1 (octanedioic acid [3-(2-(5-methoxy-1H-indol-1-yl)ethoxy)phenyl]-amide N-hydroxyamide), which was been optimized for HDAC inhibition using structure-based analyses [<CitationRef CitationID="CR21">21</CitationRef>, <CitationRef CitationID="CR22">22</CitationRef>]. The murine TNBC cell line 4 T1 and human TNBC cell line MDA-MB-231 were used to investigate the anti-tumor effects of IR combined with this novel HDACi (YCW1) and the underlying mechanism of these effects, including the types of cell death and ER stress. Furthermore, we tested the inhibitory effect of IR combined with YCW1 in a 4 T1 orthotopic breast cancer model in mice. Our results suggest that the downregulation of BNIP3 in TNBC cells significantly increased the anti-tumor effects of IR and YCW1 through the induction of autophagic cell death. Using an orthotopic breast cancer mouse model of TNBC cells, we verified that co-treatment with IR and YCW1 inhibited tumor growth.</Para>
            </Section1>
            <Section1 ID="Sec2" Type="Results">
              <Heading>Results</Heading>
              <Section2 ID="Sec3">
                <Heading>YCW1 inhibits HDAC activity and enhances cytotoxicity of IR in TNBC cells</Heading>
                <Para ID="Par9">SAHA was the first HDACi to be approved by the FDA for clinical use in cancer patients. However, some serious adverse events were reported in patients treated with SAHA [<CitationRef CitationID="CR23">23</CitationRef>]. Therefore, we investigated the use of a novel HDACi (YCW1). Our previous study indicated that YCW1 is a class I and II HDACi. Furthermore, compared with SAHA, YCW1 showed better inhibition of total HDAC activity [<CitationRef CitationID="CR22">22</CitationRef>]. In the present study, we found that YCW1 significantly enhanced toxicity in 4 T1 cells compared with SAHA in 4 T1 cells (Fig. <InternalRef RefID="Fig1">1a</InternalRef>). To further determine whether YCW1 inhibits HDAC activity in 4 T1 cells, the murine TNBC cell line was treated with YCW1 at the indicated doses to examine the acetylation level of HDAC target proteins. YCW1 induced dose-dependent acetylation of histones H3 and H4, and non-histone protein tubulin (Fig. <InternalRef RefID="Fig1">1b</InternalRef>). Next, we investigated the effects of YCW1 concentration and IR dose on 4 T1 and MDA-MB-231 cell viability (Figs. <InternalRef RefID="Fig2">2a</InternalRef> and <InternalRef RefID="Fig2">b</InternalRef>). YCW1 and IR treatment both decreased cell viability in a concentration- and dose-dependent manner, respectively. As shown in Fig. <InternalRef RefID="Fig2">2c</InternalRef>, the combined treatment with YCW1 and IR enhanced the growth inhibition of 4 T1 and MDA-MB-231 cells compared with YCW1 or IR alone.<Figure Category="Standard" Float="Yes" ID="Fig1">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 1</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Cytotoxic effects resulting from SAHA and YCW1 treatment in 4 T1 cells. <Emphasis Type="Bold">a</Emphasis> Dose-dependent effects of SAHA and YCW1 treatment on the viability of 4 T1 cells for 24 h. *, <Emphasis Type="Italic">p</Emphasis> &lt; 0.05, SAHA versus YCW1. Data are presented as the mean ± standard deviation of three independent experiments. <Emphasis Type="Bold">b</Emphasis> Concentration-dependent effects of YCW1 on histone and nonhistone proteins for 24 h in 4 T1 cells</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO1">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/12943_2016_531_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                           <Figure Category="Standard" Float="Yes" ID="Fig2">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 2</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Cytotoxic effects resulting from YCW1 and/or IR in 4 T1 and MBA-MD-231 cells. <Emphasis Type="Bold">a</Emphasis> Concentration-dependent effects of YCW1 on the viability of 4 T1 and MBA-MD-231 cells. Cells were treated with 0.5, 1, 1.5 or 2 μM of YCW1 for 48 h. <Emphasis Type="Bold">b</Emphasis> Dose-dependent effects of IR on the viability of 4 T1 and MBA-MD-231 cells. Cells were treated with 2, 4, 6 or 8 Gy of IR for 48 h. *, <Emphasis Type="Italic">p</Emphasis> &lt; 0.05, YCW1 or IR versus control group. <Emphasis Type="Bold">c</Emphasis> Cytotoxicity observed in cells treated with YCW1 (1 μM) and IR (4 Gy) for 48 h in 4 T1 and MBA-MD-231 cells. #, <Emphasis Type="Italic">p</Emphasis> &lt; 0.05, IR versus combined treatment. *, <Emphasis Type="Italic">p</Emphasis> &lt; 0.05, YCW1 versus combined treatment. Data are presented as the mean ± standard deviation of three independent experiments</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO2">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/12943_2016_531_Fig2_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                        </Para>
              </Section2>
              <Section2 ID="Sec4">
                <Heading>Combined treatment induces ER stress and autophagy in 4 T1 cells</Heading>
                <Para ID="Par10">Previous studies have demonstrated that HDACi and IR induce ER stress [<CitationRef CitationID="CR24">24</CitationRef>, <CitationRef CitationID="CR25">25</CitationRef>]. Therefore, we determined whether combined treatment with YCW1 and IR induced an ER stress response in 4 T1 cells. Our results showed that levels of inositol-requiring enzyme 1α (IRE1α) and eukaryotic initiation factor 2α (eIF2α) phosphorylation, both markers of ER stress, increased in cells treated with combined YCW1 and IR compared with those subjected to individual treatment (Fig. <InternalRef RefID="Fig3">3a</InternalRef>). Members of the Bcl-2 family act as sentinels that selectively trigger apoptosis in response to developmental cues or stress-signals such as ER stress [<CitationRef CitationID="CR26">26</CitationRef>]. We found that the Bcl-XL protein expression levels decreased in 4 T1 cells following combined treatment. Furthermore, we analyzed the types of cell death induced by combined treatment. Our results showed that the occurrence of early apoptosis in 4 T1 cells treated with YCW1 and/or IR was low (Fig. <InternalRef RefID="Fig3">3b</InternalRef>). We further analyzed the occurrence of type II programmed cell death, autophagy. Microtubule-associated protein light chain 3 (LC3) is widely used to monitor autophagy [<CitationRef CitationID="CR27">27</CitationRef>]. Thus, we applied fluorescence microscopy to determine the percentage of cells with punctate LC3 staining (Fig. <InternalRef RefID="Fig3">3c</InternalRef>). Quantitative results showed a significant increase in LC3 immunopositive dots in 4 T1 cells that received the combined treatment compared with YCW1 or IR alone. The expression of autophagic-related LC3-II, beclin 1, p62 and Atg5 proteins in 4 T1 cells after different treatments were analyzed (Fig. <InternalRef RefID="Fig3">3d</InternalRef>). We found a marked increase in the expression of LC3-II, beclin 1, p62 and Atg5 proteins in 4 T1 cells treated with YCW1 and IR, alone and in combination. The combined treatment showed a significant increase in the expression of LC3-II, beclin 1 and Atg5 proteins compared with YCW1 or IR treatment alone. By TEM, 4 T1 cells exhibited obvious autophagic vacuoles in the cytoplasm after combined treatment (Fig. <InternalRef RefID="Fig4">4</InternalRef> and Additional file <InternalRef RefID="MOESM1">1</InternalRef>: Figure S1B). Additionally, combined treatment caused a severe dilation of ER membranes, which is a sign of ER stress, compared with the control group. These results confirm that the combined treatment induced ER stress and autophagy in 4 T1 cells.<Figure Category="Standard" Float="Yes" ID="Fig3">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 3</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Measurement of cell death and ER stress in 4 T1 cells. <Emphasis Type="Bold">a</Emphasis> The expression levels of ER stress-related proteins were measured by western blot analysis following treatment with YCW1 and IR alone or in combination. Cells were treated with YCW1 (1 μM) and IR (4 Gy) for 12 h. <Emphasis Type="Bold">b</Emphasis> Early apoptosis, detected using an Annexin V apoptosis detection kit, was measured using flow cytometry. Cells were treated with YCW1 (1 μM) and IR (4 Gy) for 48 h. <Emphasis Type="Bold">c</Emphasis> Immunofluorescence staining of the LC3 protein in 4 T1 cells treated with YCW1 (1 μM) and IR (4 Gy) for 48 h. Representative cell images showing punctate LC3 distribution using a confocal microscope. Quantitative data calculating the number of LC3 dots per cell. #, <Emphasis Type="Italic">p</Emphasis> &lt; 0.05, IR versus combined treatment. *, <Emphasis Type="Italic">p</Emphasis> &lt; 0.05, YCW1 versus combined treatment. Data are presented as the mean ± standard deviation of three independent experiments. <Emphasis Type="Bold">d</Emphasis> The expression levels of autophagic-related proteins were measured by western blot analysis following treatment with YCW1 and IR alone or in combination. The densities of the bands were quantified with a computer densitometer (AlphaImager™ 2200 System Alpha Innotech Corporation, CA, USA). Cells were treated with YCW1 (1 μM) and IR (4 Gy) for 48 h. #, <Emphasis Type="Italic">p</Emphasis> &lt; 0.05, IR versus combined treatment. *, <Emphasis Type="Italic">p</Emphasis> &lt; 0.05, YCW1 versus combined treatment</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO3">
                      <ImageObject Color="Color" FileRef="MediaObjects/12943_2016_531_Fig3_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                           <Figure Category="Standard" Float="Yes" ID="Fig4">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 4</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>The ultrastructures of 4 T1 cells treated with YCW1 (1 μM) and IR (4 Gy) for 48 h were analyzed by TEM. N, nucleus. Black arrows, autophagosomes. Black arrowheads, autolysosome. White arrows, endoplasmic reticulum</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO4">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/12943_2016_531_Fig4_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                        </Para>
              </Section2>
              <Section2 ID="Sec5">
                <Heading>Autophagic cell death is induced by the combination of YCW1 and IR</Heading>
                <Para ID="Par11">Autophagy is a cytoprotective process in starving cells. However, excess autophagy can induce type II programmed cell death (autophagic cell death) [<CitationRef CitationID="CR28">28</CitationRef>]. To study the role of autophagy in combined treatment-induced cytotoxicity, cells were transfected with Atg5 shRNA then exposed to YCW1and IR. Atg5 shRNA inhibited the expression of Atg5, LC3 puncta and autophagic vacuoles (Fig. <InternalRef RefID="Fig5">5a</InternalRef>, <InternalRef RefID="Fig5">b</InternalRef> and Additional file <InternalRef RefID="MOESM1">1</InternalRef>: Figure S1). Furthermore, inhibition of autophagy by Atg5 shRNA increased the cell viability in 4 T1 cells treated with the combined treatment (Fig. <InternalRef RefID="Fig5">5c</InternalRef>). Previous studies have suggested that one of the criteria of autophagic cell death is an increase in autophagic flux, and not just an increase in the autophagic markers [<CitationRef CitationID="CR29">29</CitationRef>]. We analyzed the autophagic flux with bafilomycin A1(BAF, a vacuolar-type H<Superscript>+</Superscript>-ATPase inhibitor that blocks autophagosome-lysosome fusion). As shown in Fig. <InternalRef RefID="Fig5">5c</InternalRef>, combined treatment led to the accumulation of LC3-II in the presence of BAF. Therefore, the increase in LC3-II was not due to the blockade of autophagic degradation. The increase of LC3-II by BAF in cells treated with combined treatment likely results in autophagic flux.<Figure Category="Standard" Float="Yes" ID="Fig5">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 5</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Measurement of autophagic and cytotoxic effects in 4 T1 cells pretreated with Atg shRNA. <Emphasis Type="Bold">a</Emphasis> Western blotting for Atg5. The cells were transfected with Atg5 shRNA for 24 h. <Emphasis Type="Bold">b</Emphasis> Quantitative data calculating the number of LC3 dots per cell in the absence or presence of Atg5 shRNA. <Emphasis Type="Bold">c</Emphasis> Cytotoxic effects in the absence or presence of Atg5 shRNA. Cells were transfected with Atg5 shRNA for 24 h and were then incubated with YCW1 (1 μM) and IR (4 Gy) for 48 h. *, <Emphasis Type="Italic">p</Emphasis> &lt; 0.05, YCW1 + IR versus Atg5 shRNA + YCW1 + IR. Data are presented as the mean ± standard deviation of three independent experiments. <Emphasis Type="Bold">d</Emphasis> Western blot analysis of LC3-I and LC3-II expression in 4 T1 cells. Cells were pretreated with BAF for 1 h prior to IR treatment and then treated with YCW1 (1 μM) and IR (4 Gy) for 48 h</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO5">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/12943_2016_531_Fig5_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                        </Para>
              </Section2>
              <Section2 ID="Sec6">
                <Heading>BNIP3 expression influences the cytotoxic effects of YCW1 and IR in 4 T1 cells</Heading>
                <Para ID="Par12">To investigate whether BNIP3 is involved in combined treatment-induced cell death, we performed western blotting to detect its protein expression levels. The results showed that BNIP3 levels were significantly decreased in cells treated with combined treatment compared with those treated with YCW1 and IR alone (Fig. <InternalRef RefID="Fig6">6a</InternalRef>). Next, BNIP3 protein expression was depleted using shRNA (Fig. <InternalRef RefID="Fig6">6b</InternalRef>). We found that BNIP3 shRNA-2 inhibited more BNIP3 expression compare with BNIP3 shRNA-1. Thus, we used BNIP3 shRNA-2 to downregulate BNIP3 and investigated the role of BNIP3 in combined treatment-induced cytotoxicity and autophagy. We observed that a significant increase in LC3 immunopositive dots was observed in 4 T1 cells transfected with BNIP3 shRNA compared with the control shRNA (Fig. <InternalRef RefID="Fig6">6c</InternalRef>). Additionally, BNIP3 shRNA reduced the viability of 4 T1 cells (Fig. <InternalRef RefID="Fig6">6d</InternalRef>). To further confirm the role of BNIP3 in autophagy activation, autophagy activity was measured in 4 T1 cells expressing BNIP3. After transfection, BNIP3 expression was significantly increased (Fig. <InternalRef RefID="Fig6">6e</InternalRef>). We found that the LC3-puncta formation showed decreased when BNIP3 is overexpressed (Fig. <InternalRef RefID="Fig6">6f</InternalRef>).<Figure Category="Standard" Float="Yes" ID="Fig6">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 6</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>BNIP3 knockdown by shRNA abrogates the growth of 4 T1 cells. <Emphasis Type="Bold">a</Emphasis> The expression levels of BNIP3 in 4 T1 cells were analyzed by western blot analysis following YCW and/or IR treatment. Cells were treated with YCW1 (1 μM) and IR (4 Gy) for 48 h. <Emphasis Type="Bold">b</Emphasis> Transfection efficacy was verified by western blot analysis. BNIP3 protein expression in 4 T1 cells transfected with scramble or BNIP3 shRNA for 24 h. <Emphasis Type="Bold">c</Emphasis> Quantitative data calculating the number of LC3 dots per cell transfected with scramble or BNIP3 shRNA. *, <Emphasis Type="Italic">p</Emphasis> &lt; 0.05. <Emphasis Type="Bold">d</Emphasis> Cytotoxicity observed in cells transfected with scramble or BNIP3 shRNA using flow cytometry. *, <Emphasis Type="Italic">p</Emphasis> &lt; 0.05. <Emphasis Type="Bold">e</Emphasis> Western blot analysis of BNIP3 protein expression in cells overexpressing BNIP3. <Emphasis Type="Bold">f</Emphasis> Quantitative data calculating the number of LC3 dots in the overexpression of BNIP3. Cells were transfected with BNIP3 for 24 h and were then incubated with YCW1 (1 μM) and IR (4 Gy) for 48 h. *, <Emphasis Type="Italic">p</Emphasis> &lt; 0.05, YCW1 + IR versus BNIP3 + YCW1 + IR. Data are presented as the mean ± standard deviation of three independent experiments</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO6">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/12943_2016_531_Fig6_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                        </Para>
              </Section2>
              <Section2 ID="Sec7">
                <Heading>Tumor growth in an orthotopic breast cancer model is suppressed by combined treatment with YCW1 and IR through the induction of autophagy and the inhibition of BNIP3</Heading>
                <Para ID="Par13">We next evaluated the anti-tumor growth effect of YCW1 and IR alone, or in combination in vivo. Tumors were induced by the injection of 4 T1-Luc cells into the lactiferous ducts of the 4th mammary fat pads of female Balb/c mice. We measured the body weight and tumor volume of the mice every week. None of the treatment regimens produced any obvious signs of toxicity based on the loss of body weight (Fig. <InternalRef RefID="Fig7">7b</InternalRef>). Furthermore, no detectable toxicity was evident by biochemical examination following treatment with YCW1 or IR alone (Table <InternalRef RefID="Tab1">1</InternalRef>). In addition, we used an IVIS system to analyze bioluminescence. The results showed a gradual increase in tumor volume in the control group in a time-dependent manner. The combined treatment suppressed tumor volume compared with the control group (Fig. <InternalRef RefID="Fig7">7a</InternalRef> and <InternalRef RefID="Fig7">c</InternalRef>). Next, the expression patterns of LC3 and BNIP3 in the 4 T1 tumors were examined by IHC staining (Fig. <InternalRef RefID="Fig7">7d</InternalRef>). BNIP3 expression was decreased in the YCW1 alone, IR alone and combination groups compared with the control group. By contrast, the expression level of LC3 was increased. Tumor tissues from the mice treated with both YCW1 and IR showed lower BNIP3 and higher LC3 expression compared with the tumor tissues from mice treated with a single agent. This experiment showed that the combination of YCW1 and IR significantly inhibited BNIP3 and induced autophagic cell death in an orthotopic breast cancer model.<Figure Category="Standard" Float="Yes" ID="Fig7">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 7</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Combined treatment with YCW1 and IR enhances the anti-tumor effects in an orthotopic breast cancer model. <Emphasis Type="Bold">a</Emphasis> 4 T1-luc cells were injected into the mammary fat pads of Balb/c mice, observed for luciferase signals and photographed using an IVIS 200. <Emphasis Type="Bold">b</Emphasis> Measurement of body weight in Balb/c mice taken once per week. <Emphasis Type="Bold">c</Emphasis> Quantification of the luciferase signals. *, <Emphasis Type="Italic">p</Emphasis> &lt; 0.05, versus control. <Emphasis Type="Bold">d</Emphasis> IHC staining of orthotopic tumor tissues from the mice. IHC was used to determine the expression levels of LC3 and BNIP3 (×100 objective magnification). The percentage of LC3 and BNIP3-positive cells was determined using HistoQuest software (TissueGnostics)</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO7">
                      <ImageObject Color="Color" FileRef="MediaObjects/12943_2016_531_Fig7_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                           <Table Float="Yes" ID="Tab1">
                    <Caption Language="En">
                      <CaptionNumber>Table 1</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Biochemical tests including GOT, GPT, albumin and BUN</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <tgroup cols="6">
                      <colspec align="left" colname="c1" colnum="1"/>
                      <colspec align="left" colname="c2" colnum="2"/>
                      <colspec align="left" colname="c3" colnum="3"/>
                      <colspec align="left" colname="c4" colnum="4"/>
                      <colspec align="left" colname="c5" colnum="5"/>
                      <colspec align="left" colname="c6" colnum="6"/>
                      <thead>
                        <row>
                          <entry colname="c1"/>
                          <entry colname="c2"/>
                          <entry nameend="c6" namest="c3">
                            <SimplePara>4 T1-Luc cells</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1">
                            <SimplePara>Item/Group</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>Normal</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>Control</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>YCW1</SimplePara>
                          </entry>
                          <entry colname="c5">
                            <SimplePara>IR</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>YCW1 + IR</SimplePara>
                          </entry>
                        </row>
                      </thead>
                      <tbody>
                        <row>
                          <entry colname="c1">
                            <SimplePara>GOT (U/l)</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>137.67 ± 42.17</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>147.33 ± 13.72</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>184.00 ± 32.32</SimplePara>
                          </entry>
                          <entry colname="c5">
                            <SimplePara>181.67 ± 29.35</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>180.67 ± 18.22</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1">
                            <SimplePara>GPT (U/l)</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>48.00 ± 10.60</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>35.33 ± 3.18</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>33.67 ± 2.67</SimplePara>
                          </entry>
                          <entry colname="c5">
                            <SimplePara>33.33 ± 2.19</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>40.33 ± 7.97</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1">
                            <SimplePara>Albumin (g/dl)</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>2.67 ± 0.13</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>2.37 ± 0.24</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>2.37 ± 0.12</SimplePara>
                          </entry>
                          <entry colname="c5">
                            <SimplePara>2.37 ± 0.15</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>2.23 ± 0.13</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1">
                            <SimplePara>BUN (mg/dl)</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>21.60 ± 2.63</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>30.50 ± 10.42</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>26.73 ± 1.07</SimplePara>
                          </entry>
                          <entry colname="c5">
                            <SimplePara>25.47 ± 1.60</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>26.53 ± 1.87</SimplePara>
                          </entry>
                        </row>
                      </tbody>
                    </tgroup>
                  </Table>
                        </Para>
              </Section2>
            </Section1>
            <Section1 ID="Sec8" Type="Discussion">
              <Heading>Discussion</Heading>
              <Para ID="Par14">TNBC is the most invasive and aggressive among the breast cancer subtypes and there is no clinical therapy specific for patients with TNBC [<CitationRef CitationID="CR30">30</CitationRef>]. In the present study, we found that the combination of a novel HDACi (YCW1) and IR may have anti-tumor potential against TNBC both in vitro and in vivo (Figs. <InternalRef RefID="Fig2">2</InternalRef> and <InternalRef RefID="Fig7">7</InternalRef>). Moreover, our previous study demonstrated that YCW1 induced a broad spectrum of anticancer activities in lung cancer cell and animal models. It has been showed that HDACi induced cell death in many tumors and had less toxicity in normal cells [<CitationRef CitationID="CR17">17</CitationRef>, <CitationRef CitationID="CR18">18</CitationRef>]. However, HDACi have demonstrated limited clinical benefit for patients with solid tumors [<CitationRef CitationID="CR31">31</CitationRef>]. In our study, we used a novel HDACi, YCW1, and examined the combination effect of YCW1 and IR in TNBC cells. YCW1 showed a better inhibition of total HDAC activity and significantly enhanced toxicity compared with SAHA [<CitationRef CitationID="CR22">22</CitationRef>] (Fig. <InternalRef RefID="Fig1">1a</InternalRef>). The combined treatment with YCW1 and IR enhanced the growth inhibition of 4 T1 and MDA-MB-231 cells compared with YCW1 or IR alone (Fig. <InternalRef RefID="Fig2">2</InternalRef>). Furthermore, YCW1 caused no detectable toxicity as determined by either biochemical examination or in terms of the loss of body weight (Fig. <InternalRef RefID="Fig7">7b</InternalRef> and Table <InternalRef RefID="Tab1">1</InternalRef>). Therefore, YCW1 is a potential HDAC inhibitor and enhances radiosensitivity in TNBC cells.</Para>
              <Para ID="Par15">HDACi cause ER stress, apoptosis and autophagy in many tumors [<CitationRef CitationID="CR6">6</CitationRef>, <CitationRef CitationID="CR17">17</CitationRef>]. Previous research has shown that treatment of cancer cells with HDACi induced autophagy which promotes cancer cell survival when apoptosis induction is inhibited. Moreover, autophagy inhibition resulted in a higher level of apoptosis in response to SAHA treatment [<CitationRef CitationID="CR32">32</CitationRef>]. Rao et al. indicated that combination of autophagy inhibitor and HDACi induced the accumulation of toxic polyubiquitylated proteins and caused inhibitory effects on TNBC cell growth [<CitationRef CitationID="CR33">33</CitationRef>]. However, there are also numerous reports in the literature showing the pro-death function of autophagy. HDACi can induce caspase-independent autophagic cell death and have clear clinical implications in treating cancers with apoptotic defects [<CitationRef CitationID="CR34">34</CitationRef>, <CitationRef CitationID="CR35">35</CitationRef>]. Therefore, the role of autophagy in regulating cancer cell death or survival remains controversial. Recent studies have investigated the induction of ER stress as a novel strategy for treating malignancies [<CitationRef CitationID="CR36">36</CitationRef>, <CitationRef CitationID="CR37">37</CitationRef>]. ER stress triggers unfolded protein response (UPR) pathways, including the IRE1 pathway, the PKR-like ER-resistant kinase pathway and the activating transcription factor 6 pathway [<CitationRef CitationID="CR38">38</CitationRef>]. Data accumulated by us and others have revealed that IR activates ER stress and UPR pathways through the induction of DNA damage [<CitationRef CitationID="CR24">24</CitationRef>, <CitationRef CitationID="CR39">39</CitationRef>]. Here, IRE1α and phosphorylated eIF2α, which are both UPR-related proteins, increased in cells treated with combined YCW1 and IR (Fig. <InternalRef RefID="Fig3">3a</InternalRef>). Using TEM, the ultrastructures of the 4 T1 cells indicated ER stress after the treatment with combined treatment (Fig. <InternalRef RefID="Fig4">4</InternalRef>). Evidence indicating that ER stress can induce cell death, including apoptosis and autophagy, has been reported [<CitationRef CitationID="CR40">40</CitationRef>, <CitationRef CitationID="CR41">41</CitationRef>]. We found that combined treatment mainly induced autophagy and a small amount of apoptosis in 4 T1 cells (Figs. <InternalRef RefID="Fig3">3</InternalRef>, <InternalRef RefID="Fig4">4</InternalRef> and Additional file <InternalRef RefID="MOESM1">1</InternalRef>: Figure S1). In our in vivo study, tumor tissues from the mice treated with combined treatment showed higher autopahgic levels compared with mice treated with a single agent (Fig. <InternalRef RefID="Fig7">7d</InternalRef>). However, the role of autophagy in regulating cancer cell death or survival remains controversial. Furthermore, an increase in autophagic flux may be the a key factor that modulates autophagy to cell death [<CitationRef CitationID="CR29">29</CitationRef>]. The present study shows that Atg5 shRNA decreased combined treatment-induced cytotoxicity (Fig. <InternalRef RefID="Fig5">5c</InternalRef>). Additionally, the combined treatment caused autophagic flux (Fig. <InternalRef RefID="Fig5">5d</InternalRef>). Therefore, our results showed that the combination treatment with YCW1 and IR induced autophagic cell death in TNBC cells.</Para>
              <Para ID="Par16">Members of the Bcl-2 family are contained in multiprotein complexes at the ER, where they regulate diverse cellular processes including autophagy, calcium homeostasis and the unfolded-protein response [<CitationRef CitationID="CR42">42</CitationRef>]. The Bcl-2 family comprises three subfamilies, an anti-apoptotic family, a pro-apoptotic multi-domain family and a pro-apoptotic BH3-only protein family [<CitationRef CitationID="CR43">43</CitationRef>]. Recent evidence shows that this family affects not only apoptosis but also autophagy [<CitationRef CitationID="CR19">19</CitationRef>, <CitationRef CitationID="CR44">44</CitationRef>]. In the present study, Bcl-XL protein expression decreased in 4 T1 cells following combined treatment (Fig. <InternalRef RefID="Fig3">3a</InternalRef>). Although BNIP3 is in the pro-apoptotic BH3-only protein family, it was recently found to increase resistance to apoptosis, and it was implicated that BNIP3 may also play an important role in autophagy [<CitationRef CitationID="CR45">45</CitationRef>, <CitationRef CitationID="CR46">46</CitationRef>]. Moreover, growing evidence has shown that the overexpression of BNIP3 can be detected in many malignancies, such as glioma, breast cancer and prostate cancer [<CitationRef CitationID="CR14">14</CitationRef>, <CitationRef CitationID="CR47">47</CitationRef>]. In addition, BNIP3 was not identified in normal breast but was up-regulated in breast cancer [<CitationRef CitationID="CR15">15</CitationRef>]. Park et al. indicated that BNIP3 degradation was triggered by autophagy and could be regulated by mTORC1 and AMPK [<CitationRef CitationID="CR48">48</CitationRef>]. In this study, we found that BNIP3 significantly decreased in cells or tumors following combined treatment compared with those that received YCW1 or IR alone (Figs. <InternalRef RefID="Fig6">6a</InternalRef> and <InternalRef RefID="Fig7">7d</InternalRef>). 4 T1 cells transfected with BNIP3 shRNA showed a significant increase the number of autophagic cells and reduced the viability compared with the control shRNA (Fig. <InternalRef RefID="Fig6">6c</InternalRef> and <InternalRef RefID="Fig6">d</InternalRef>). Furthermore, the overexpression of BNIP3 decreased autophagy (Fig. <InternalRef RefID="Fig6">6f</InternalRef>). Therefore, combined treatment induced autophagic cell death through the inhibition of BNIP3 in TNBC cells.</Para>
            </Section1>
            <Section1 ID="Sec9" Type="Conclusion">
              <Heading>Conclusions</Heading>
              <Para ID="Par17">Taken together, these data suggest that the combination of YCW1 and IR exerts a cytotoxic effect on TNBC cells that is associated with increased levels of autophagy and ER stress. More importantly, BNIP3 was degraded by the combined treatment-induced autophagy. This combination benefit was also observed in vivo using an orthotopic breast cancer model. Our data show that combining YCW1 and IR and targeting BNIP3 are therapeutic options that should be further investigated for the treatment of TNBC.</Para>
            </Section1>
            <Section1 ID="Sec10" Type="MaterialsAndMethods">
              <Heading>Methods</Heading>
              <Section2 ID="Sec11">
                <Heading>Preparation of YCW1</Heading>
                <Para ID="Par18">The complete chemical name of YCW1 is octanedioic acid [3-(2-(5-methoxy-1H-indol-1-yl)ethoxy)phenyl]-amide N-hydroxyamide. Requests for this compound should be sent to wjhuang@tmu.edu.tw.</Para>
              </Section2>
              <Section2 ID="Sec12">
                <Heading>Cell culture</Heading>
                <Para ID="Par19">The murine breast cancer cell line 4 T1 (ATCC CRL-2539) and human breast cancer cell line MDA-MB-231 (ATCC HTB-26) were obtained from the American Type Culture Collection (ATCC). The luciferase-expressing murine breast cancer cell line 4 T1-Luc was obtained from Dr. M.L. Kuo (Institute of Toxicology, National Taiwan University, Taipei, Taiwan) [<CitationRef CitationID="CR49">49</CitationRef>]. The cells were cultured in Dulbecco’s modified essential medium (DMEM) (Gibco BRL, Grand Island, NY, USA) supplemented with an antibiotic containing 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco BRL, Grand Island, NY, USA) and 10 % fetal bovine serum (HyClone, South Logan, UT, USA). The cells were incubated in a humidified atmosphere containing 5 % CO<Subscript>2</Subscript> at 37 °C. Exponentially growing cells were detached using 0.05 % trypsin-EDTA (Gibco BRL, Grand Island, NY) in DMEM.</Para>
              </Section2>
              <Section2 ID="Sec13">
                <Heading>Irradiation treatment and cell viability assay</Heading>
                <Para ID="Par20">IR was performed with 6 MV X-rays using a linear accelerator (Digital M Mevatron Accelerator, Siemens Medical Systems, CA, USA) at a dose rate of 5 Gy/min. An additional 2 cm of a tissue-equivalent bolus was placed on the top of the plastic tissue-culture flasks to ensure electronic equilibrium, and 10 cm of a tissue-equivalent material was placed under the flasks to achieve full backscatter. Cells were immediately treated with YCW1 following IR treatment. Next, the cells were centrifuged and resuspended in 0.1 ml PBS. Each cell suspension (0.02 ml) was mixed with 0.02 ml of a trypan blue solution (0.2 % in PBS). After 1 or 2 min, each solution was analyzed on a hemocytometer, with blue-stained cells counted as nonviable.</Para>
              </Section2>
              <Section2 ID="Sec14">
                <Heading>Determination of early apoptosis</Heading>
                <Para ID="Par21">Apoptosis was assessed by quantifying the translocation of phosphatidylserine to the cell surface, detected with Annexin V staining (Calbiochem, San Diego, CA, USA). Experiments were conducted according to our previous reports [<CitationRef CitationID="CR5">5</CitationRef>, <CitationRef CitationID="CR50">50</CitationRef>].</Para>
              </Section2>
              <Section2 ID="Sec15">
                <Heading>Immunofluorescence microscopy</Heading>
                <Para ID="Par22">The cells were cultured on coverslips. Cells were harvested and fixed in 4 % paraformaldehyde and blocked with 1 % BSA for 30 min. This was followed by incubation with a specific antibody against LC3 (MBL, Japan) for 1 h. After washing, the cells were labeled with a DyLight™ 488-conjugated affinipure goat anti-rabbit IgG (Jackson Immuno-Research Laboratories, PA, USA) for 1 h and with DAPI. Finally, the cells were washed in PBS, covered with a coverslip, and examined with a fluorescence microscope or confocal microscope (Carl Zeiess LSM780, Instrument Development Center, NCKU). To quantify the number of LC3 dots per cell, a minimum of 50 cells per sample was counted.</Para>
              </Section2>
              <Section2 ID="Sec16">
                <Heading>Transmission electron microscopy (TEM)</Heading>
                <Para ID="Par23">Cells were trypsinized and harvested, then fixed for 1 h in a solution containing 2.5 % glutaraldehyde and 2 % paraformaldehyde in 0.1 M cacodylate buffer, pH 7.3. After fixation, the samples were postfixed with buffer containing 1 % OsO<Subscript>4</Subscript> for 30 min. Ultra-thin sections were subsequently observed under a transmission electron microscope (JEOL JEM-1200EX, Japan) at 100 kV.</Para>
              </Section2>
              <Section2 ID="Sec17">
                <Heading>Western blot analysis</Heading>
                <Para ID="Par24">Total cellular protein lysate was prepared by harvesting cells in protein extraction buffer for 1 h at 4 °C, as described previously [<CitationRef CitationID="CR4">4</CitationRef>]. GAPDH expression represented the protein loading control. Anti-GAPDH, anti-BNIP3, anti-IRE1α, phospho-eIF2α and anti-beclin 1 antibodies were obtained from Abcam (Cambridge, MA, USA); anti-LC3 and anti-eIF2α antibodies were obtained from Abgent (San Diego, CA, USA); anti-acetyl-histone H3 and acetyl-histone H4 antibodies were obtained from Millipore (Bedford, MA, USA); anti-acetyl-tubulin antibody was obtained from Sigma (St. Louis, Missouri, USA); anti-Bcl-XL antibody was obtained from Cell Signaling Technology (Ipswich, MA, USA); and anti-p62/SQSTM1 antibody was obtained from MBL (Nagoya, Japan).</Para>
              </Section2>
              <Section2 ID="Sec18">
                <Heading>Transfection of shRNA and plasmids</Heading>
                <Para ID="Par25">We used Arrest-In Transfection Reagent (Thermo, MA, USA) to transfect cells according to the manufacturer’s protocol. RNAi reagents were obtained from the National RNAi Core Facility located at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, supported by the National Core Facility Program for Biotechnology Grants of NSC (NSC 100-2319-B-001-002). The mouse library is referred to as TRC-Mm 1.0. Individual clones are identified as shRNA TRCN0000072184, shRNA TRCN0000009691, TRCN0000099432, TRCN0000099433, TRCN0000375819 and shRNA TRCN0000229458. BNIP3 plasmid was obtained from OriGene Technologies Inc. (Rockville, MD, USA).</Para>
              </Section2>
              <Section2 ID="Sec19">
                <Heading>Orthotopic breast cancer model</Heading>
                <Para ID="Par26">All experiments on mice were performed according to the guidelines of our institute (the Guide for Care and Use of Laboratory Animals, Medical College, National Cheng Kung University). The animal use protocol listed below has been reviewed and approved by the Institutional Animal Care and Use Committee of National Cheng Kung University, Taiwan (Approval No: 104232). Six week-old female Balb/c mice were acquired from the National Laboratory Animal Center (Taiwan). The animals were housed five per cage at 24 ± 2 °C and 50 % ± 10 % relative humidity and subjected to a 12-h light/12-h dark cycle. 4 T1-Lluc cells (5 × 10<Superscript>4</Superscript> cells in 0.2 ml of PBS) were injected into the lactiferous ducts of the 4th mammary fat pads in the female Balb/c mice. The mice were randomized into four treatment groups (5 mice per group): (1) Control (DMSO), (2) 25 mg/kg YCW1 three times per week for three weeks, (3) a single dose of 4 Gy IR, or (4) a combination of treatments with 25 mg/kg YCW1 three times per week and a single dose of 4 Gy IR. Bioluminescence imaging was conducted using an IVIS 200 imaging system coupled to a data acquisition computer running Living Image Software (XENOGEN). Before imaging, the mice were anesthetized with isoflurane and injected i.p with 150 mg/kg body weight endotoxin-free luciferase substrate (VivoGlo™, Promega). Body weights were measured once per week and used as an indicator of the systemic toxicity of the treatment. There were no deaths in any group during the experimental period. Mice were sacrificed via CO<Subscript>2</Subscript> exposure. After sacrificing, the tumor tissues were formalin fixed and paraffin embedded for immunohistochemistry.</Para>
              </Section2>
              <Section2 ID="Sec20">
                <Heading>Immunohistochemical (IHC) staining analysis</Heading>
                <Para ID="Par27">Paraffin-embedded tissue sections (4 μm) were dried, deparaffinized, and rehydrated. Following microwave pretreatment in citrate buffer (pH 6.0; for antigen retrieval), the slides were immersed in 3 % hydrogen peroxide for 20 min to block the activity of endogenous peroxidases. After extensive washing with PBS, the slides were incubated overnight at 4 °C with the anti-LC3 (MBL, Japan) or anti-BNIP3 (Abcam, MA, USA) antibody. The sections were then incubated with a secondary antibody for 1 h at room temperature, and the slides were developed using the STARR TREK Universal HRP detection kit (Biocare Medical, Concord, CA). Finally, the slides were counterstained using hematoxylin. Each slide was imaged at low magnification (×100).</Para>
              </Section2>
              <Section2 ID="Sec21">
                <Heading>Biochemistry tests</Heading>
                <Para ID="Par28">Whole blood samples from the treated mice were collected by intracardiac puncture and centrifuged at 2000 × g for 20 min to separate the serum. The biochemistry evaluation included assessing the glutamate oxaloacetate transaminase (GOT) activity, glutamate pyruvate transaminase (GPT) activity, albumin levels and blood urea nitrogen (BUN) levels. All experiments and procedures were performed in accordance with the Institutional Care Use Committee guidelines.</Para>
              </Section2>
              <Section2 ID="Sec22">
                <Heading>Statistical analysis</Heading>
                <Para ID="Par29">Data are expressed as the mean ± SD. Statistical significance was determined using Student’s <Emphasis Type="Italic">t</Emphasis>-test for comparisons between the means or one-way analysis of variance with post-hoc Dunnett’s test [<CitationRef CitationID="CR51">51</CitationRef>]. Differences were considered significant when <Emphasis Type="Italic">p</Emphasis> &lt; 0.05.</Para>
              </Section2>
            </Section1>
            <Section1 ID="Sec23">
              <Heading>Abbreviations</Heading>
              <Para ID="Par30">3-MA, 3-methyladenine; AO, acridine orange; ATF6, activating transcription factor 6; AVOs, acidic vesicular organelles; BAF, bafilomycin A1; BNIP3, Bcl-2/adenovirus E1B 19 kDa protein-interacting protein 3; ER, endoplasmic reticulum; IR, ionizing radiation; IRE1α, inositol-requiring enzyme 1α; PERK, PKR-like ER-resistant kinase; UPR, unfolded protein response; UPS, ubiquitin-proteasome system.</Para>
            </Section1>
          </Body>
          <BodyRef FileRef="BodyRef/PDF/12943_2016_Article_531.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Acknowledgments>
              <Heading>Acknowledgments</Heading>
              <SimplePara>This study was supported by the Ministry of Science and Technology, Taiwan (MOST 103-2314-B-006-060-MY2, MOST 104-2320-B-038-065, NSC 100-2325-B-400-012, NSC 101-2325-B-400-010 and NSC 102-2325-B-400 -010), the Taipei Medical University, Taipei, Taiwan (TMU103-AE1-B28) and the Chi Mei Medical Center, Tainan, Taiwan (CMNCKU10422).</SimplePara>
              <FormalPara ID="FPar1" RenderingStyle="Style1">
                <Heading>Authors’ contributions</Heading>
                <Para ID="Par31">HWC, YLY, YHH, WJH and YFL participated in data collection and analysis. HWC, YCW, SYH, PL and YJW participated in the design of the study. HWC, SYH, PL and YJW participated in the writing of the manuscript and data interpretation. All authors read and approved the final manuscript.</Para>
              </FormalPara>
              <FormalPara ID="FPar2" RenderingStyle="Style1">
                <Heading>Competing interests</Heading>
                <Para ID="Par32">The authors declare that they have no competing interests.</Para>
              </FormalPara>
            </Acknowledgments>
            <Appendix ID="App1" OutputMedium="Online">
              <Section1 ID="Sec24">
                <Heading>Additional file</Heading>
                <Para ID="Par33">
                  <MediaObject ID="MOESM1">
                    <DataObject FileRef="MediaObjects/12943_2016_531_MOESM1_ESM.doc">
                      <Caption Language="En">
                        <CaptionNumber>Additional file 1:</CaptionNumber>
                        <CaptionContent>
                          <SimplePara>Supplementary results. (DOC 3159 kb)</SimplePara>
                        </CaptionContent>
                      </Caption>
                    </DataObject>
                  </MediaObject>
                </Para>
              </Section1>
            </Appendix>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>BD</Initials>
                    <FamilyName>Lehmann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JA</Initials>
                    <FamilyName>Bauer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ME</Initials>
                    <FamilyName>Sanders</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AB</Initials>
                    <FamilyName>Chakravarthy</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Shyr</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2011</Year>
                  <ArticleTitle Language="En">Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</ArticleTitle>
                  <JournalTitle>J Clin Invest</JournalTitle>
                  <VolumeID>121</VolumeID>
                  <FirstPage>2750</FirstPage>
                  <LastPage>67</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3MXovVKgu78%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1172/JCI45014</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>21633166</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3127435</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Dent</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Trudeau</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KI</Initials>
                    <FamilyName>Pritchard</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WM</Initials>
                    <FamilyName>Hanna</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HK</Initials>
                    <FamilyName>Kahn</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CA</Initials>
                    <FamilyName>Sawka</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Triple-negative breast cancer: clinical features and patterns of recurrence</ArticleTitle>
                  <JournalTitle>Clin Cancer Res</JournalTitle>
                  <VolumeID>13</VolumeID>
                  <FirstPage>4429</FirstPage>
                  <LastPage>34</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1158/1078-0432.CCR-06-3045</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>17671126</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>GA</Initials>
                    <FamilyName>Viani</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GB</Initials>
                    <FamilyName>Manta</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EC</Initials>
                    <FamilyName>Fonseca</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LI</Initials>
                    <FamilyName>Fendi</FamilyName>
                    <Particle>De</Particle>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SL</Initials>
                    <FamilyName>Afonso</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EJ</Initials>
                    <FamilyName>Stefano</FamilyName>
                  </BibAuthorName>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">Whole brain radiotherapy with radiosensitizer for brain metastases</ArticleTitle>
                  <JournalTitle>J Exp Clin Cancer Res</JournalTitle>
                  <VolumeID>28</VolumeID>
                  <FirstPage>1</FirstPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1186/1756-9966-28-1</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>19126230</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2648943</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Viani GA, Manta GB, Fonseca EC, De Fendi LI, Afonso SL, Stefano EJ. Whole brain radiotherapy with radiosensitizer for brain metastases. J Exp Clin Cancer Res. 2009;28:1.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HW</Initials>
                    <FamilyName>Chiu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SY</Initials>
                    <FamilyName>Ho</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HR</Initials>
                    <FamilyName>Guo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YJ</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">Combination treatment with arsenic trioxide and irradiation enhances autophagic effects in U118-MG cells through increased mitotic arrest and regulation of PI3K/Akt and ERK1/2 signaling pathways</ArticleTitle>
                  <JournalTitle>Autophagy</JournalTitle>
                  <VolumeID>5</VolumeID>
                  <FirstPage>472</FirstPage>
                  <LastPage>83</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1MXnvVyrsL0%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.4161/auto.5.4.7759</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>19242099</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Chiu HW, Ho SY, Guo HR, Wang YJ. Combination treatment with arsenic trioxide and irradiation enhances autophagic effects in U118-MG cells through increased mitotic arrest and regulation of PI3K/Akt and ERK1/2 signaling pathways. Autophagy. 2009;5:472–83.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HW</Initials>
                    <FamilyName>Chiu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Lin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YA</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SY</Initials>
                    <FamilyName>Ho</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YJ</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Combination treatment with arsenic trioxide and irradiation enhances cell-killing effects in human fibrosarcoma cells in vitro and in vivo through induction of both autophagy and apoptosis</ArticleTitle>
                  <JournalTitle>Autophagy</JournalTitle>
                  <VolumeID>6</VolumeID>
                  <FirstPage>353</FirstPage>
                  <LastPage>65</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXpt1WjtLY%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.4161/auto.6.3.11229</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20200477</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Chiu HW, Lin JH, Chen YA, Ho SY, Wang YJ. Combination treatment with arsenic trioxide and irradiation enhances cell-killing effects in human fibrosarcoma cells in vitro and in vivo through induction of both autophagy and apoptosis. Autophagy. 2010;6:353–65.</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HW</Initials>
                    <FamilyName>Chiu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YL</Initials>
                    <FamilyName>Yeh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YC</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WJ</Initials>
                    <FamilyName>Huang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YA</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YS</Initials>
                    <FamilyName>Chiou</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2013</Year>
                  <ArticleTitle Language="En">Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo</ArticleTitle>
                  <JournalTitle>PLoS One</JournalTitle>
                  <VolumeID>8</VolumeID>
                  <FirstPage>e76340</FirstPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3sXhs1Cjsr7P</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1371/journal.pone.0076340</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>24130769</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3794942</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Chiu HW, Yeh YL, Wang YC, Huang WJ, Chen YA, Chiou YS, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. PLoS One. 2013;8:e76340.</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Dent</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Yacoub</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PB</Initials>
                    <FamilyName>Fisher</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MP</Initials>
                    <FamilyName>Hagan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Grant</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">MAPK pathways in radiation responses</ArticleTitle>
                  <JournalTitle>Oncogene</JournalTitle>
                  <VolumeID>22</VolumeID>
                  <FirstPage>5885</FirstPage>
                  <LastPage>96</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXmslemtLo%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/sj.onc.1206701</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>12947395</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S. MAPK pathways in radiation responses. Oncogene. 2003;22:5885–96.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>OC</Initials>
                    <FamilyName>Schuurbiers</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Kaanders</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HF</Initials>
                    <FamilyName>Heijden</FamilyName>
                    <Particle>van der</Particle>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RP</Initials>
                    <FamilyName>Dekhuijzen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WJ</Initials>
                    <FamilyName>Oyen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Bussink</FamilyName>
                  </BibAuthorName>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer</ArticleTitle>
                  <JournalTitle>J Thorac Oncol</JournalTitle>
                  <VolumeID>4</VolumeID>
                  <FirstPage>761</FirstPage>
                  <LastPage>7</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1097/JTO.0b013e3181a1084f</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>19404218</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Schuurbiers OC, Kaanders JH, van der Heijden HF, Dekhuijzen RP, Oyen WJ, Bussink J. The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol. 2009;4:761–7.</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Li</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GI</Initials>
                    <FamilyName>Tennekoon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Birnbaum</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MA</Initials>
                    <FamilyName>Marchionni</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JL</Initials>
                    <FamilyName>Rutkowski</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Neuregulin signaling through a PI3K/Akt/Bad pathway in Schwann cell survival</ArticleTitle>
                  <JournalTitle>Mol Cell Neurosci</JournalTitle>
                  <VolumeID>17</VolumeID>
                  <FirstPage>761</FirstPage>
                  <LastPage>7</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1006/mcne.2000.0967</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>11312610</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Li Y, Tennekoon GI, Birnbaum M, Marchionni MA, Rutkowski JL. Neuregulin signaling through a PI3K/Akt/Bad pathway in Schwann cell survival. Mol Cell Neurosci. 2001;17:761–7.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>TT</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>Phang</FamilyName>
                  </BibAuthorName>
                  <Year>1995</Year>
                  <ArticleTitle Language="En">Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7</ArticleTitle>
                  <JournalTitle>Cancer Res</JournalTitle>
                  <VolumeID>55</VolumeID>
                  <FirstPage>2487</FirstPage>
                  <LastPage>9</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2MXmtlWrsL8%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>7780952</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Wang TT, Phang JM. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res. 1995;55:2487–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>RA</Initials>
                    <FamilyName>Hanna</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MN</Initials>
                    <FamilyName>Quinsay</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AM</Initials>
                    <FamilyName>Orogo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Giang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Rikka</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AB</Initials>
                    <FamilyName>Gustafsson</FamilyName>
                  </BibAuthorName>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">Microtubule-associated protein 1 light chain 3 (LC3) interacts with Bnip3 protein to selectively remove endoplasmic reticulum and mitochondria via autophagy</ArticleTitle>
                  <JournalTitle>J Biol Chem</JournalTitle>
                  <VolumeID>287</VolumeID>
                  <FirstPage>19094</FirstPage>
                  <LastPage>104</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC38XnvVSqsrc%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1074/jbc.M111.322933</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>22505714</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3365942</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hanna RA, Quinsay MN, Orogo AM, Giang K, Rikka S, Gustafsson AB. Microtubule-associated protein 1 light chain 3 (LC3) interacts with Bnip3 protein to selectively remove endoplasmic reticulum and mitochondria via autophagy. J Biol Chem. 2012;287:19094–104.</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Zhang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Z</Initials>
                    <FamilyName>Zhang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Sandhu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X</Initials>
                    <FamilyName>Ma</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X</Initials>
                    <FamilyName>Yang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JD</Initials>
                    <FamilyName>Geiger</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Evidence of oxidative stress-induced BNIP3 expression in amyloid beta neurotoxicity</ArticleTitle>
                  <JournalTitle>Brain Res</JournalTitle>
                  <VolumeID>1138</VolumeID>
                  <FirstPage>221</FirstPage>
                  <LastPage>30</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXit1Kju7s%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.brainres.2006.12.086</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>17274962</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zhang S, Zhang Z, Sandhu G, Ma X, Yang X, Geiger JD, et al. Evidence of oxidative stress-induced BNIP3 expression in amyloid beta neurotoxicity. Brain Res. 2007;1138:221–30.</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>TR</Initials>
                    <FamilyName>Burton</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SB</Initials>
                    <FamilyName>Gibson</FamilyName>
                  </BibAuthorName>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">The role of Bcl-2 family member BNIP3 in cell death and disease: NIPping at the heels of cell death</ArticleTitle>
                  <JournalTitle>Cell Death Differ</JournalTitle>
                  <VolumeID>16</VolumeID>
                  <FirstPage>515</FirstPage>
                  <LastPage>23</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1MXjtFaqsbY%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/cdd.2008.185</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>19136941</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3158804</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Burton TR, Gibson SB. The role of Bcl-2 family member BNIP3 in cell death and disease: NIPping at the heels of cell death. Cell Death Differ. 2009;16:515–23.</BibUnstructured>
              </Citation>
              <Citation ID="CR14">
                <CitationNumber>14.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>TR</Initials>
                    <FamilyName>Burton</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ES</Initials>
                    <FamilyName>Henson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Baijal</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DD</Initials>
                    <FamilyName>Eisenstat</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SB</Initials>
                    <FamilyName>Gibson</FamilyName>
                  </BibAuthorName>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">The pro-cell death Bcl-2 family member, BNIP3, is localized to the nucleus of human glial cells: Implications for glioblastoma multiforme tumor cell survival under hypoxia</ArticleTitle>
                  <JournalTitle>Int J Cancer</JournalTitle>
                  <VolumeID>118</VolumeID>
                  <FirstPage>1660</FirstPage>
                  <LastPage>9</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD28XislKls78%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/ijc.21547</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>16217754</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3158801</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Burton TR, Henson ES, Baijal P, Eisenstat DD, Gibson SB. The pro-cell death Bcl-2 family member, BNIP3, is localized to the nucleus of human glial cells: Implications for glioblastoma multiforme tumor cell survival under hypoxia. Int J Cancer. 2006;118:1660–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR15">
                <CitationNumber>15.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HM</Initials>
                    <FamilyName>Sowter</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Ferguson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Pym</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Watson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SB</Initials>
                    <FamilyName>Fox</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Han</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade</ArticleTitle>
                  <JournalTitle>J Pathol</JournalTitle>
                  <VolumeID>201</VolumeID>
                  <FirstPage>573</FirstPage>
                  <LastPage>80</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXlsVGmsQ%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/path.1486</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>14648660</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sowter HM, Ferguson M, Pym C, Watson P, Fox SB, Han C, et al. Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade. J Pathol. 2003;201:573–80.</BibUnstructured>
              </Citation>
              <Citation ID="CR16">
                <CitationNumber>16.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PA</Initials>
                    <FamilyName>Marks</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WS</Initials>
                    <FamilyName>Xu</FamilyName>
                  </BibAuthorName>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">Histone deacetylase inhibitors: Potential in cancer therapy</ArticleTitle>
                  <JournalTitle>J Cell Biochem</JournalTitle>
                  <VolumeID>107</VolumeID>
                  <FirstPage>600</FirstPage>
                  <LastPage>8</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1MXosFOiurg%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/jcb.22185</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>19459166</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2766855</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem. 2009;107:600–8.</BibUnstructured>
              </Citation>
              <Citation ID="CR17">
                <CitationNumber>17.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PA</Initials>
                    <FamilyName>Marks</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">The clinical development of histone deacetylase inhibitors as targeted anticancer drugs</ArticleTitle>
                  <JournalTitle>Expert Opin Investig Drugs</JournalTitle>
                  <VolumeID>19</VolumeID>
                  <FirstPage>1049</FirstPage>
                  <LastPage>66</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXhtVWqu7vP</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1517/13543784.2010.510514</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20687783</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>4077324</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs. 2010;19:1049–66.</BibUnstructured>
              </Citation>
              <Citation ID="CR18">
                <CitationNumber>18.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PP</Initials>
                    <FamilyName>Pandolfi</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Histone deacetylases and transcriptional therapy with their inhibitors</ArticleTitle>
                  <JournalTitle>Cancer Chemother Pharmacol</JournalTitle>
                  <VolumeID>48</VolumeID>
                  <IssueID>Suppl 1</IssueID>
                  <FirstPage>S17</FirstPage>
                  <LastPage>9</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXot1GisLc%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s002800100322</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>11587360</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Pandolfi PP. Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemother Pharmacol. 2001;48 Suppl 1:S17–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR19">
                <CitationNumber>19.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TH</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MY</Initials>
                    <FamilyName>Ahn</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Jung</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WS</Initials>
                    <FamilyName>Choi</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">Sirtinol, a class III HDAC inhibitor, induces apoptotic and autophagic cell death in MCF-7 human breast cancer cells</ArticleTitle>
                  <JournalTitle>Int J Oncol</JournalTitle>
                  <VolumeID>41</VolumeID>
                  <FirstPage>1101</FirstPage>
                  <LastPage>9</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC38XhtlWhu7rP</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>22751989</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Wang J, Kim TH, Ahn MY, Lee J, Jung JH, Choi WS, et al. Sirtinol, a class III HDAC inhibitor, induces apoptotic and autophagic cell death in MCF-7 human breast cancer cells. Int J Oncol. 2012;41:1101–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR20">
                <CitationNumber>20.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Dokmanovic</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Clarke</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PA</Initials>
                    <FamilyName>Marks</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Histone deacetylase inhibitors: overview and perspectives</ArticleTitle>
                  <JournalTitle>Mol Cancer Res</JournalTitle>
                  <VolumeID>5</VolumeID>
                  <FirstPage>981</FirstPage>
                  <LastPage>9</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXhtFygsLvN</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1158/1541-7786.MCR-07-0324</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>17951399</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res. 2007;5:981–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR21">
                <CitationNumber>21.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>WJ</Initials>
                    <FamilyName>Huang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CC</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SW</Initials>
                    <FamilyName>Chao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CC</Initials>
                    <FamilyName>Yu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CY</Initials>
                    <FamilyName>Yang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Guh</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2011</Year>
                  <ArticleTitle Language="En">Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors</ArticleTitle>
                  <JournalTitle>Eur J Med Chem</JournalTitle>
                  <VolumeID>46</VolumeID>
                  <FirstPage>4042</FirstPage>
                  <LastPage>9</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3MXhtV2rt7bP</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.ejmech.2011.06.002</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>21712146</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Huang WJ, Chen CC, Chao SW, Yu CC, Yang CY, Guh JH, et al. Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors. Eur J Med Chem. 2011;46:4042–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR22">
                <CitationNumber>22.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>WJ</Initials>
                    <FamilyName>Huang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YA</Initials>
                    <FamilyName>Tang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MY</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YJ</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>FH</Initials>
                    <FamilyName>Hu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TW</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2014</Year>
                  <ArticleTitle Language="En">A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies</ArticleTitle>
                  <JournalTitle>Cancer Lett</JournalTitle>
                  <VolumeID>346</VolumeID>
                  <FirstPage>84</FirstPage>
                  <LastPage>93</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3sXitVWntL3N</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.canlet.2013.12.016</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>24355296</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Huang WJ, Tang YA, Chen MY, Wang YJ, Hu FH, Wang TW, et al. A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies. Cancer Lett. 2014;346:84–93.</BibUnstructured>
              </Citation>
              <Citation ID="CR23">
                <CitationNumber>23.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Duvic</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Talpur</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X</Initials>
                    <FamilyName>Ni</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Zhang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Hazarika</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Kelly</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)</ArticleTitle>
                  <JournalTitle>Blood</JournalTitle>
                  <VolumeID>109</VolumeID>
                  <FirstPage>31</FirstPage>
                  <LastPage>9</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXivVyrt7g%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1182/blood-2006-06-025999</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>16960145</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>1785068</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR24">
                <CitationNumber>24.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>He</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SO</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>O</Initials>
                    <FamilyName>Kwon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SJ</Initials>
                    <FamilyName>Jeong</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MS</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HG</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">ATM blocks tunicamycin-induced endoplasmic reticulum stress</ArticleTitle>
                  <JournalTitle>FEBS Lett</JournalTitle>
                  <VolumeID>583</VolumeID>
                  <FirstPage>903</FirstPage>
                  <LastPage>8</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1MXis1aqtbw%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.febslet.2009.02.002</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>19302790</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>He L, Kim SO, Kwon O, Jeong SJ, Kim MS, Lee HG, et al. ATM blocks tunicamycin-induced endoplasmic reticulum stress. FEBS Lett. 2009;583:903–8.</BibUnstructured>
              </Citation>
              <Citation ID="CR25">
                <CitationNumber>25.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>YL</Initials>
                    <FamilyName>Liu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PM</Initials>
                    <FamilyName>Yang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CT</Initials>
                    <FamilyName>Shun</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MS</Initials>
                    <FamilyName>Wu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JR</Initials>
                    <FamilyName>Weng</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CC</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma</ArticleTitle>
                  <JournalTitle>Autophagy</JournalTitle>
                  <VolumeID>6</VolumeID>
                  <FirstPage>1057</FirstPage>
                  <LastPage>65</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXhs1WltrjP</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.4161/auto.6.8.13365</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20962572</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Liu YL, Yang PM, Shun CT, Wu MS, Weng JR, Chen CC. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy. 2010;6:1057–65.</BibUnstructured>
              </Citation>
              <Citation ID="CR26">
                <CitationNumber>26.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Reimertz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Kogel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Rami</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Chittenden</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Prehn</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Gene expression during ER stress-induced apoptosis in neurons: induction of the BH3-only protein Bbc3/PUMA and activation of the mitochondrial apoptosis pathway</ArticleTitle>
                  <JournalTitle>J Cell Biol</JournalTitle>
                  <VolumeID>162</VolumeID>
                  <FirstPage>587</FirstPage>
                  <LastPage>97</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXms1Sqtrg%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1083/jcb.200305149</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>12913114</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2173793</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Reimertz C, Kogel D, Rami A, Chittenden T, Prehn JH. Gene expression during ER stress-induced apoptosis in neurons: induction of the BH3-only protein Bbc3/PUMA and activation of the mitochondrial apoptosis pathway. J Cell Biol. 2003;162:587–97.</BibUnstructured>
              </Citation>
              <Citation ID="CR27">
                <CitationNumber>27.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Mizushima</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Yoshimori</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">How to interpret LC3 immunoblotting</ArticleTitle>
                  <JournalTitle>Autophagy</JournalTitle>
                  <VolumeID>3</VolumeID>
                  <FirstPage>542</FirstPage>
                  <LastPage>5</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXhtlOhs7jL</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.4161/auto.4600</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>17611390</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy. 2007;3:542–5.</BibUnstructured>
              </Citation>
              <Citation ID="CR28">
                <CitationNumber>28.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Bursch</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Ellinger</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Gerner</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>U</Initials>
                    <FamilyName>Frohwein</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Schulte-Hermann</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Programmed cell death (PCD). Apoptosis, autophagic PCD, or others?</ArticleTitle>
                  <JournalTitle>Ann N Y Acad Sci</JournalTitle>
                  <VolumeID>926</VolumeID>
                  <FirstPage>1</FirstPage>
                  <LastPage>12</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXnt1altA%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1749-6632.2000.tb05594.x</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>11193023</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bursch W, Ellinger A, Gerner C, Frohwein U, Schulte-Hermann R. Programmed cell death (PCD). Apoptosis, autophagic PCD, or others? Ann N Y Acad Sci. 2000;926:1–12.</BibUnstructured>
              </Citation>
              <Citation ID="CR29">
                <CitationNumber>29.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HM</Initials>
                    <FamilyName>Shen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Codogno</FamilyName>
                  </BibAuthorName>
                  <Year>2011</Year>
                  <ArticleTitle Language="En">Autophagic cell death: Loch Ness monster or endangered species?</ArticleTitle>
                  <JournalTitle>Autophagy</JournalTitle>
                  <VolumeID>7</VolumeID>
                  <FirstPage>457</FirstPage>
                  <LastPage>65</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC38XitF2jsg%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.4161/auto.7.5.14226</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>21150268</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Shen HM, Codogno P. Autophagic cell death: Loch Ness monster or endangered species? Autophagy. 2011;7:457–65.</BibUnstructured>
              </Citation>
              <Citation ID="CR30">
                <CitationNumber>30.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>WD</Initials>
                    <FamilyName>Foulkes</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>IE</Initials>
                    <FamilyName>Smith</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JS</Initials>
                    <FamilyName>Reis-Filho</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Triple-negative breast cancer</ArticleTitle>
                  <JournalTitle>N Engl J Med</JournalTitle>
                  <VolumeID>363</VolumeID>
                  <FirstPage>1938</FirstPage>
                  <LastPage>48</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXhsVCltr7P</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1056/NEJMra1001389</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>21067385</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.</BibUnstructured>
              </Citation>
              <Citation ID="CR31">
                <CitationNumber>31.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Tan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Cang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Ma</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RL</Initials>
                    <FamilyName>Petrillo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Liu</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents</ArticleTitle>
                  <JournalTitle>J Hematol Oncol</JournalTitle>
                  <VolumeID>3</VolumeID>
                  <FirstPage>5</FirstPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1186/1756-8722-3-5</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20132536</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2827364</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010;3:5.</BibUnstructured>
              </Citation>
              <Citation ID="CR32">
                <CitationNumber>32.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Gammoh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Lam</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Puente</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Ganley</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PA</Initials>
                    <FamilyName>Marks</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X</Initials>
                    <FamilyName>Jiang</FamilyName>
                  </BibAuthorName>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death</ArticleTitle>
                  <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                  <VolumeID>109</VolumeID>
                  <FirstPage>6561</FirstPage>
                  <LastPage>5</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC38Xmslyjtb0%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.1204429109</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>22493260</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3340088</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Gammoh N, Lam D, Puente C, Ganley I, Marks PA, Jiang X. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc Natl Acad Sci U S A. 2012;109:6561–5.</BibUnstructured>
              </Citation>
              <Citation ID="CR33">
                <CitationNumber>33.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Balusu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Fiskus</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>U</Initials>
                    <FamilyName>Mudunuru</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Venkannagari</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Chauhan</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells</ArticleTitle>
                  <JournalTitle>Mol Cancer Ther</JournalTitle>
                  <VolumeID>11</VolumeID>
                  <FirstPage>973</FirstPage>
                  <LastPage>83</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC38Xltl2nuro%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1158/1535-7163.MCT-11-0979</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>22367781</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rao R, Balusu R, Fiskus W, Mudunuru U, Venkannagari S, Chauhan L, et al. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. Mol Cancer Ther. 2012;11:973–83.</BibUnstructured>
              </Citation>
              <Citation ID="CR34">
                <CitationNumber>34.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Shao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Z</Initials>
                    <FamilyName>Gao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PA</Initials>
                    <FamilyName>Marks</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X</Initials>
                    <FamilyName>Jiang</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Apoptotic and autophagic cell death induced by histone deacetylase inhibitors</ArticleTitle>
                  <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                  <VolumeID>101</VolumeID>
                  <FirstPage>18030</FirstPage>
                  <LastPage>5</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXjsl2nsQ%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.0408345102</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>15596714</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>539807</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 2004;101:18030–5.</BibUnstructured>
              </Citation>
              <Citation ID="CR35">
                <CitationNumber>35.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>YJ</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AJ</Initials>
                    <FamilyName>Won</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Jung</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Yoon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>BM</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells</ArticleTitle>
                  <JournalTitle>Int J Med Sci</JournalTitle>
                  <VolumeID>9</VolumeID>
                  <FirstPage>881</FirstPage>
                  <LastPage>93</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC38Xhslyisb3E</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.7150/ijms.5011</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>23155362</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3498753</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Lee YJ, Won AJ, Lee J, Jung JH, Yoon S, Lee BM, et al. Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells. Int J Med Sci. 2012;9:881–93.</BibUnstructured>
              </Citation>
              <Citation ID="CR36">
                <CitationNumber>36.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Liu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Ye</FamilyName>
                  </BibAuthorName>
                  <Year>2011</Year>
                  <ArticleTitle Language="En">Proteostasis regulation at the endoplasmic reticulum: a new perturbation site for targeted cancer therapy</ArticleTitle>
                  <JournalTitle>Cell Res</JournalTitle>
                  <VolumeID>21</VolumeID>
                  <FirstPage>867</FirstPage>
                  <LastPage>83</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3MXmvFOgt7w%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/cr.2011.75</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>21537343</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3203708</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Liu Y, Ye Y. Proteostasis regulation at the endoplasmic reticulum: a new perturbation site for targeted cancer therapy. Cell Res. 2011;21:867–83.</BibUnstructured>
              </Citation>
              <Citation ID="CR37">
                <CitationNumber>37.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Sato</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Asano</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Isono</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Ito</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Asano</FamilyName>
                  </BibAuthorName>
                  <Year>2014</Year>
                  <ArticleTitle Language="En">Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells</ArticleTitle>
                  <JournalTitle>BMC Urol</JournalTitle>
                  <VolumeID>14</VolumeID>
                  <FirstPage>71</FirstPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1186/1471-2490-14-71</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>25176354</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>4153447</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sato A, Asano T, Isono M, Ito K, Asano T. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells. BMC Urol. 2014;14:71.</BibUnstructured>
              </Citation>
              <Citation ID="CR38">
                <CitationNumber>38.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Ron</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Walter</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Signal integration in the endoplasmic reticulum unfolded protein response</ArticleTitle>
                  <JournalTitle>Nat Rev Mol Cell Biol</JournalTitle>
                  <VolumeID>8</VolumeID>
                  <FirstPage>519</FirstPage>
                  <LastPage>29</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXmvVaktLY%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/nrm2199</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>17565364</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007;8:519–29.</BibUnstructured>
              </Citation>
              <Citation ID="CR39">
                <CitationNumber>39.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HW</Initials>
                    <FamilyName>Chiu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WH</Initials>
                    <FamilyName>Fang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YL</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MD</Initials>
                    <FamilyName>Wu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GF</Initials>
                    <FamilyName>Yuan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SY</Initials>
                    <FamilyName>Ho</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">Monascuspiloin enhances the radiation sensitivity of human prostate cancer cells by stimulating endoplasmic reticulum stress and inducing autophagy</ArticleTitle>
                  <JournalTitle>PLoS One</JournalTitle>
                  <VolumeID>7</VolumeID>
                  <FirstPage>e40462</FirstPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC38XhtVWgsLrF</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1371/journal.pone.0040462</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>22802963</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3389026</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Chiu HW, Fang WH, Chen YL, Wu MD, Yuan GF, Ho SY, et al. Monascuspiloin enhances the radiation sensitivity of human prostate cancer cells by stimulating endoplasmic reticulum stress and inducing autophagy. PLoS One. 2012;7:e40462.</BibUnstructured>
              </Citation>
              <Citation ID="CR40">
                <CitationNumber>40.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>IM</Initials>
                    <FamilyName>Germano</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Emdad</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ZA</Initials>
                    <FamilyName>Qadeer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Binello</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Uzzaman</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas</ArticleTitle>
                  <JournalTitle>Cancer Gene Ther</JournalTitle>
                  <VolumeID>17</VolumeID>
                  <FirstPage>664</FirstPage>
                  <LastPage>74</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXmvFeiu7w%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/cgt.2010.31</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20523363</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2923667</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Germano IM, Emdad L, Qadeer ZA, Binello E, Uzzaman M. Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas. Cancer Gene Ther. 2010;17:664–74.</BibUnstructured>
              </Citation>
              <Citation ID="CR41">
                <CitationNumber>41.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>DM</Initials>
                    <FamilyName>Benbrook</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Long</FamilyName>
                  </BibAuthorName>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">Integration of autophagy, proteasomal degradation, unfolded protein response and apoptosis</ArticleTitle>
                  <JournalTitle>Exp Oncol</JournalTitle>
                  <VolumeID>34</VolumeID>
                  <FirstPage>286</FirstPage>
                  <LastPage>97</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC38XhvFSiu7jP</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>23070014</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Benbrook DM, Long A. Integration of autophagy, proteasomal degradation, unfolded protein response and apoptosis. Exp Oncol. 2012;34:286–97.</BibUnstructured>
              </Citation>
              <Citation ID="CR42">
                <CitationNumber>42.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CA</Initials>
                    <FamilyName>Hetz</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">ER stress signaling and the BCL-2 family of proteins: from adaptation to irreversible cellular damage</ArticleTitle>
                  <JournalTitle>Antioxid Redox Signal</JournalTitle>
                  <VolumeID>9</VolumeID>
                  <FirstPage>2345</FirstPage>
                  <LastPage>55</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXht1GrsLrI</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1089/ars.2007.1793</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>17854276</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hetz CA. ER stress signaling and the BCL-2 family of proteins: from adaptation to irreversible cellular damage. Antioxid Redox Signal. 2007;9:2345–55.</BibUnstructured>
              </Citation>
              <Citation ID="CR43">
                <CitationNumber>43.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Tomek</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Akiyama</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CR</Initials>
                    <FamilyName>Dass</FamilyName>
                  </BibAuthorName>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy</ArticleTitle>
                  <JournalTitle>J Pharm Pharmacol</JournalTitle>
                  <VolumeID>64</VolumeID>
                  <FirstPage>1695</FirstPage>
                  <LastPage>702</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC38Xhsl2iu7rF</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.2042-7158.2012.01526.x</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>23146031</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Tomek M, Akiyama T, Dass CR. Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy. J Pharm Pharmacol. 2012;64:1695–702.</BibUnstructured>
              </Citation>
              <Citation ID="CR44">
                <CitationNumber>44.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Shi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HN</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ST</Initials>
                    <FamilyName>Xie</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Luo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CY</Initials>
                    <FamilyName>Sun</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>XL</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Antimicrobial peptaibols, novel suppressors of tumor cells, targeted calcium-mediated apoptosis and autophagy in human hepatocellular carcinoma cells</ArticleTitle>
                  <JournalTitle>Mol Cancer</JournalTitle>
                  <VolumeID>9</VolumeID>
                  <FirstPage>26</FirstPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1186/1476-4598-9-26</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20122248</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2825246</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Shi M, Wang HN, Xie ST, Luo Y, Sun CY, Chen XL, et al. Antimicrobial peptaibols, novel suppressors of tumor cells, targeted calcium-mediated apoptosis and autophagy in human hepatocellular carcinoma cells. Mol Cancer. 2010;9:26.</BibUnstructured>
              </Citation>
              <Citation ID="CR45">
                <CitationNumber>45.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Zhang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PA</Initials>
                    <FamilyName>Ney</FamilyName>
                  </BibAuthorName>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">Role of BNIP3 and NIX in cell death, autophagy, and mitophagy</ArticleTitle>
                  <JournalTitle>Cell Death Differ</JournalTitle>
                  <VolumeID>16</VolumeID>
                  <FirstPage>939</FirstPage>
                  <LastPage>46</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1MXnsV2qs7Y%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/cdd.2009.16</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>19229244</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2768230</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zhang J, Ney PA. Role of BNIP3 and NIX in cell death, autophagy, and mitophagy. Cell Death Differ. 2009;16:939–46.</BibUnstructured>
              </Citation>
              <Citation ID="CR46">
                <CitationNumber>46.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>TR</Initials>
                    <FamilyName>Burton</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DD</Initials>
                    <FamilyName>Eisenstat</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SB</Initials>
                    <FamilyName>Gibson</FamilyName>
                  </BibAuthorName>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">BNIP3 (Bcl-2 19 kDa interacting protein) acts as transcriptional repressor of apoptosis-inducing factor expression preventing cell death in human malignant gliomas</ArticleTitle>
                  <JournalTitle>J Neurosci</JournalTitle>
                  <VolumeID>29</VolumeID>
                  <FirstPage>4189</FirstPage>
                  <LastPage>99</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1MXktlaktb4%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1523/JNEUROSCI.5747-08.2009</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>19339613</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3262017</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Burton TR, Eisenstat DD, Gibson SB. BNIP3 (Bcl-2 19 kDa interacting protein) acts as transcriptional repressor of apoptosis-inducing factor expression preventing cell death in human malignant gliomas. J Neurosci. 2009;29:4189–99.</BibUnstructured>
              </Citation>
              <Citation ID="CR47">
                <CitationNumber>47.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HM</Initials>
                    <FamilyName>Sowter</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PJ</Initials>
                    <FamilyName>Ratcliffe</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Watson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AH</Initials>
                    <FamilyName>Greenberg</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AL</Initials>
                    <FamilyName>Harris</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors</ArticleTitle>
                  <JournalTitle>Cancer Res</JournalTitle>
                  <VolumeID>61</VolumeID>
                  <FirstPage>6669</FirstPage>
                  <LastPage>73</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXntFaisrc%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>11559532</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 2001;61:6669–73.</BibUnstructured>
              </Citation>
              <Citation ID="CR48">
                <CitationNumber>48.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CW</Initials>
                    <FamilyName>Park</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SM</Initials>
                    <FamilyName>Hong</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ES</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Kwon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KT</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HG</Initials>
                    <FamilyName>Nam</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2013</Year>
                  <ArticleTitle Language="En">BNIP3 is degraded by ULK1-dependent autophagy via MTORC1 and AMPK</ArticleTitle>
                  <JournalTitle>Autophagy</JournalTitle>
                  <VolumeID>9</VolumeID>
                  <FirstPage>345</FirstPage>
                  <LastPage>60</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3sXltl2ht78%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.4161/auto.23072</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>23291726</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3590255</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Park CW, Hong SM, Kim ES, Kwon JH, Kim KT, Nam HG, et al. BNIP3 is degraded by ULK1-dependent autophagy via MTORC1 and AMPK. Autophagy. 2013;9:345–60.</BibUnstructured>
              </Citation>
              <Citation ID="CR49">
                <CitationNumber>49.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JY</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YA</Initials>
                    <FamilyName>Tang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SM</Initials>
                    <FamilyName>Huang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HF</Initials>
                    <FamilyName>Juan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LW</Initials>
                    <FamilyName>Wu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YC</Initials>
                    <FamilyName>Sun</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2011</Year>
                  <ArticleTitle Language="En">A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways</ArticleTitle>
                  <JournalTitle>Cancer Res</JournalTitle>
                  <VolumeID>71</VolumeID>
                  <FirstPage>473</FirstPage>
                  <LastPage>83</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3MXlsFKlsg%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1158/0008-5472.CAN-10-1303</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>21224350</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Chen JY, Tang YA, Huang SM, Juan HF, Wu LW, Sun YC, et al. A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Res. 2011;71:473–83.</BibUnstructured>
              </Citation>
              <Citation ID="CR50">
                <CitationNumber>50.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HW</Initials>
                    <FamilyName>Chiu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YS</Initials>
                    <FamilyName>Ho</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YJ</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <Year>2011</Year>
                  <ArticleTitle Language="En">Arsenic trioxide induces autophagy and apoptosis in human glioma cells in vitro and in vivo through downregulation of survivin</ArticleTitle>
                  <JournalTitle>J Mol Med (Berl)</JournalTitle>
                  <VolumeID>89</VolumeID>
                  <FirstPage>927</FirstPage>
                  <LastPage>41</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3MXhtVajurrP</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s00109-011-0763-1</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Chiu HW, Ho YS, Wang YJ. Arsenic trioxide induces autophagy and apoptosis in human glioma cells in vitro and in vivo through downregulation of survivin. J Mol Med (Berl). 2011;89:927–41.</BibUnstructured>
              </Citation>
              <Citation ID="CR51">
                <CitationNumber>51.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PL</Initials>
                    <FamilyName>Peng</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WH</Initials>
                    <FamilyName>Kuo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HC</Initials>
                    <FamilyName>Tseng</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>FP</Initials>
                    <FamilyName>Chou</FamilyName>
                  </BibAuthorName>
                  <Year>2008</Year>
                  <ArticleTitle Language="En">Synergistic tumor-killing effect of radiation and berberine combined treatment in lung cancer: the contribution of autophagic cell death</ArticleTitle>
                  <JournalTitle>Int J Radiat Oncol Biol Phys</JournalTitle>
                  <VolumeID>70</VolumeID>
                  <FirstPage>529</FirstPage>
                  <LastPage>42</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1cXosVGlug%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.ijrobp.2007.08.034</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>18207031</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Peng PL, Kuo WH, Tseng HC, Chou FP. Synergistic tumor-killing effect of radiation and berberine combined treatment in lung cancer: the contribution of autophagic cell death. Int J Radiat Oncol Biol Phys. 2008;70:529–42.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
